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Profibrotic epithelial phenotype: a 
central role for MRTF and TAZ
Janne Folke Bialik1,4, Mei Ding1, Pam speight1, Qinghong Dan1, Maria Zena Miranda1,3, 
Caterina Di Ciano-Oliveira1, Michael M. Kofler1, Ori D. Rotstein1, Stine F. Pedersen  4, 
Katalin Szászi1,2 & András Kapus1,2,3
Epithelial injury is a key initiator of fibrosis but - in contrast to the previous paradigm - the epithelium 
in situ does not undergo wide-spread epithelial-mesenchymal/myofibroblast transition (EMT/EMyT). 
Instead, it assumes a Profibrotic Epithelial Phenotype (PEP) characterized by fibrogenic cytokine 
production. The transcriptional mechanisms underlying PEP are undefined. As we have shown that 
two RhoA/cytoskeleton-regulated transcriptional coactivators, Myocardin-related transcription factor 
(MRTF) and TAZ, are indispensable for EMyT, we asked if they might mediate PEP as well. Here we 
show that mechanical stress (cyclic stretch) increased the expression of transforming growth factor-β1 
(TGFβ1), connective tissue growth factor (CTGF), platelet-derived growth factor and Indian Hedgehog 
mRNA in LLC-PK1 tubular cells. These responses were mitigated by siRNA-mediated silencing or 
pharmacological inhibition of MRTF (CCG-1423) or TAZ (verteporfin). RhoA inhibition exerted similar 
effects. Unilateral ureteral obstruction, a murine model of mechanically-triggered kidney fibrosis, 
induced tubular RhoA activation along with overexpression/nuclear accumulation of MRTF and TAZ, 
and increased transcription of the above-mentioned cytokines. Laser capture microdissection revealed 
TAZ, TGFβ1 and CTGF induction specifically in the tubular epithelium. CCG-1423 suppressed total renal 
and tubular expression of these proteins. Thus, MRTF regulates epithelial TAZ expression, and both 
MRTF and TAZ are critical mediators of PEP-related epithelial cytokine production.
Chronic kidney disease (CKD), affecting 12% of the North-American population is considered an “epidemic”1. 
Renal fibrosis, characterized by excessive extracellular matrix deposition and consequent disruption of the kidney 
architecture is the final common pathogenic mechanism through which CKD, independent of etiology, pro-
gresses toward end-stage kidney disease2–5. Ever since the myofibroblast was recognized as the central cellular 
mediator of fibrogenesis6, understanding the origins and activation of this mesenchymal cell type have become 
the focus of fibrosis research7,8. This scenario poses a mechanistic challenge. There is general consensus that 
epithelial injury (due to inflammatory, hypoxic, metabolic or obstructive/mechanical insults) is an essential trig-
gering factor in tubulointerstitial fibrosis9–11. In fact, epithelium-targeted expression of damage molecules (e.g. 
cell cycle inhibitors, cholera toxin) is sufficient to provoke profound fibrosis12,13. On the other hand, the executors 
of fibrotic tissue remodeling are mesenchymal cells, including fibroblasts and their contractile, α-smooth muscle 
actin (αSMA)-expressing counterparts, the myofibroblasts. What is the link then between epithelial initiation and 
mesenchymal execution?
The previous paradigm attributed a direct role to the tubular epithelium in (myo)fibroblast generation via 
epithelial-mesenchymal transition. This notion was based on histological “snapshots” showing the co-existence 
of epithelial and mesenchymal markers in the injured epithelium in vivo (reviewed in14–16) and the undebated 
capacity of tubular cells to transition to myofibroblasts in vitro17,18. Early fate-tracing experiments proposed that 
nearly 40% of myofibroblasts might originate from tubular cells19. However, subsequent lineage tracking studies 
challenged this view, claiming that EMT plays no role in fibrogenesis20–22. A recent analysis provided a more 
nuanced view, proposing that although full EMT occurs during fibrogenesis, it is a rare event accounting for only 
a small portion (<5%) of myofibroblasts23. Accordingly, an alternative paradigm is emerging, which assigns a 
crucial but indirect role to the epithelium in fibrogenesis. Upon injury, tubular cells attain an activated state, which 
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Figure 1. Mechanical stress induces the expression of fibrogenic cytokines in tubular cells via MRTF- and 
TAZ-dependent mechanisms. LLC-PK1 cells were grown to confluence on Flexcell membranes and transfected 
with non-related (NR), MRTF-A + B- (50 nM each) or TAZ-specific (50 nM) siRNA for 48 h (a,c,e,g), or 
serum-deprived overnight and pretreated with vehicle (Veh), CCG-1423 (CCG, 5 μM) or verteporfin (VP, 
1 μM) for 30 min (b,d,f,h), as shown. Cells were then left unchallenged (No stretch) or subjected to cyclic 
stretch (Stretch, 10% elongation at 1 Hz) for 3 h. The pharmacological inhibitors were present throughout 
the course of the experiment. Cells were lysed, total cellular mRNA was isolated and reverse-transcribed 
and qPCR was performed using primers targeting TGFβ1 (a,b), CTGF (c,d), PDGF-B (e,f) and IHH (g,h). 
The expression of cytokine mRNAs was normalized to GAPDH in the same samples, and data is presented 
as fold changes compared to the untreated and unchallenged samples (n = 3, in duplicate). To assess residual 
activation after inhibitory interventions, statistical analysis was also performed between no-stretch + inhibitor 
and stretch + inhibitor conditions. TGFβ: non-stretch siMRTF and siTAZ vs. stretch siMRTF and siTAZ, 
p < 0.05 and p < 0.0001; non-stretch CCG and VP vs. stretch CCG and VP, p < 0.01 and p < 0.05. CTGF: 
non-stretch siMRTF and siTAZ vs. stretch siMRTF and siTAZ, ns and p < 0.01; non-stretch CCG and VP vs. 
3Scientific RepoRts |          (2019) 9:4323  | https://doi.org/10.1038/s41598-019-40764-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
we term “profibrotic epithelial phenotype” or PEP. This may be regarded as a partial EMT24,25, which does not go 
“all the way” to fibroblast/myofibroblast transition. Instead, its major characteristic is a secretory state. Indeed, 
the epithelium has been shown to be the source of potent fibrogenic mediators including transforming growth 
factor β (TGFβ1), connective tissue growth factor (CTGF), Platelet-derived Growth Factor (PDGF), and Indian 
Hedgehog (IHH)12,26–29. These in turn activate the neighboring mesenchymal cells, promoting fibroblast/pericyte 
proliferation and migration, extracellular matrix (ECM deposition and myofibroblast transition10. However, while 
PEP may be crucial for fibrogenesis, the signaling/transcriptional mechanisms underlying the evolution of this 
state remain poorly understood.
Previous work in our lab has focused on molecular mechanisms underlying transcriptional reprogramming 
during full-blown epithelial-myofibroblast transition (EMyT), characterized by α-SMA expression. We have 
shown that an intact tubular epithelium is highly resistant to myofibroblast transition, inasmuch that TGFβ1, 
the most potent fibrogenic and EMT-inducing cytokine is insufficient, in itself, to provoke EMyT30–32. The 
required second hit is increased contractility and cytoskeletal remodeling, which can be induced by cell contact 
injury or mechanical stress30–35. Searching for the molecular mechanisms, we have shown that two Rho GTPase/
cytoskeleton-regulated transcriptional coactivators, myocardin-related transcription factor (MRTF) and tran-
scriptional co-activator with PDZ-binding motif (TAZ) are indispensable for EMyT31,32,34,35. Both MRTF and 
TAZ are central mediators in mechanotransduction36,37, regulated at the level of their nucleo-cytoplasmic shut-
tling. Increased actin polymerization, myosin phosphorylation (contractility) or loss of cell contacts, which are 
well-known features of epithelial injury, have all been shown to facilitate nuclear accumulation of MRTF31,32,38–40 
and TAZ31,41,42. In the nucleus, MRTF interacts with serum response factor (SRF) and this complex drives gene 
expression via the CC(A/T)6GG cis- element, the CArG-box43. TAZ (and its paralog YAP), which in addition 
to their regulation by the cytoskeleton are also controlled by the Hippo kinase pathway44, activate TEADs and 
other transcription factors in the nucleus45. Furthermore, we and others have shown that MRTF and TAZ engage 
in a multilevel crosstalk with each other and with elements of TGFβ1 signaling (Smad3)35,46,47. We found that 
MRTF can regulate TAZ expression and that TAZ interacts with MRTF and Smad3, and primes the epithelium 
for TGFβ1-induced transformation34,35,48. Moreover, both MRTF49,50 and TAZ51–53 have emerged as mediators of 
organ fibrosis.
Given the essential roles of MRTF and TAZ in EMyT, we asked if these factors may also be mediators of PEP, 
the chief characteristic of which is epithelial cytokine production. To address this key question, we used two 
approaches: we assessed in vitro whether interference with MRTF or TAZ signaling alters mechanically-induced 
cytokine production in tubular cells. Further, using unilateral ureteral obstruction (UUO), a mechanical model 
of renal fibrosis, we tested whether pharmacological inhibition of MRTF alters fibrogenic TAZ and cytokine 
expression in the whole kidney and the tubular epithelium. Our data suggest that MRTF and TAZ are important 
mediators of PEP and therefore are promising pharmacological targets to interfere with changes in epithelial 
plasticity, a key driver of fibrogenesis.
Results
Inhibition of MRTF, TAZ or RhoA strongly suppresses mechanical stress-induced fibrogenic 
cytokine expression in epithelial cells. Initially we tested whether mechanical stress, a relevant inducer 
of fibrosis54,55, alters fibrogenic cytokine expression in kidney tubular cells, and if so whether such responses might 
be dependent on MRTF and/or TAZ signaling. Since cyclic stretch is an adequate mimic of pathophysiologic 
tubular mechanostress56,57, and we have previously shown that it induces robust MRTF and TAZ translocation in 
LLC-PK1 proximal tubular cells35, we used this stimulus for these proof-of-principle experiments. The applied 
3-hour stretch regimen significantly increased mRNA levels of all of the examined fibrogenic cytokines, namely 
TGFβ1, CTGF, PDGF-B, and IHH (Fig. 1). To assess the involvement of MRTF and/or TAZ, we downregulated 
these molecules by the respective siRNAs. Similar to our previous findings35,58 we obtained >80% reduction in 
the corresponding protein levels (Fig. 1a, inset) (Extended blots for all figures are shown in Supplementary Fig. 1). 
Importantly, MRTF A + B or TAZ silencing completely abolished or significantly mitigated the stretch-triggered 
increase in all of the investigated cytokine mRNAs (Fig. 1a,c,e,g). We next tested whether small molecule inhib-
itors of these pathways, which can also be applied in vivo, could also reduce mechanically induced cytokine 
production. CCG-1423 inhibits MRTF’s nuclear translocation and its binding to SRF59,60, whereas verteporfin 
destabilizes TAZ/YAP and prevents their interaction with TEAD53,61,62. Both CCG-1423 and verteporfin signif-
icantly mitigated the stretch-induced rise in the mRNA levels of all four cytokines, exerting complete or partial 
suppression (Fig. 1b,d,f,h).
While multiple inputs can activate MRTF and TAZ, RhoA activation and the ensuing actin polymerization 
are key inputs in the context of mechanotransduction36. To test if RhoA activation plays a significant role in 
mechanically induced fibrogenic cytokine expression, we pretreated LLC-PK1 cells with Rhosin, an inhibitor 
of the interaction of RhoA with its guanine nucleotide exchange factors63. This strategy was chosen because 
Rhosin did not alter cell viability or the attachment of epithelial cells to the stretchable membranes in these 
short-term experiments. In non-stretched cells, Rhosin elevated the basal mRNA expression of some cytokines 
(TGFβ1, PDGF), while it had no effect on others (CTGF, IHH) (Fig. 2a). This finding might be due to a RhoA 
stretch CCG and VP, p < 0.0001 and p < 0.0001. PDGF: non-stretch siMRTF and siTAZ vs. stretch siMRTF 
and siTAZ, p < 0.0001 and p < 0.0001; non-stretch CCG and VP vs. stretch CCG and VP, ns and p < 0.001. 
IHH: non-stretch siMRTF and siTAZ vs. stretch siMRTF and siTAZ, p < 0.0001 and ns; non-stretch CCG 
and VP vs. stretch CCG and VP, ns and ns. The representative Western blots (inset in panel a) document the 
downregulation of MRTF and TAZ by the corresponding siRNAs.
4Scientific RepoRts |          (2019) 9:4323  | https://doi.org/10.1038/s41598-019-40764-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
inhibition-induced shift in the activity of other Rho family small GTPases, which might also impact cytokine 
expression. More importantly, Rhosin entirely abolished the stretch-induced increase in expression of all four 
cytokines, resulting in significantly lower cytokine mRNA expression in Rhosin- vs. vehicle-treated stretched cells 
(Fig. 2a). Accordingly, Rhosin prevented the stretch-provoked nuclear translocation of both MRTF (Fig. 2b) and 
TAZ (Fig. 2c). Interestingly, Rhosin appeared to promote the accumulation of TAZ in cytosolic puncta (Fig. 2c).
Taken together, these experiments show that mechanical stress induces fibrogenic cytokine expression in renal 
tubular cells in a RhoA -, MRTF- and TAZ-dependent manner.
MRTF is a key regulator of TAZ expression and fibrogenic cytokine production in the early 
phase of renal fibrogenesis. Next, we asked whether MRTF and TAZ are also relevant regulators of 
cytokine expression during fibrogenesis. To approach this question, we chose an obstructive nephropathy model, 
UUO because it triggers fibrosis primarily by epithelial stress, exerted by a mechanical factor (high intratubular 
pressure)64. As our goal was to delineate events in the early (epithelial) phase of fibrogenesis, in most experiments 
we used short-term (3-day) UUO.
We first tested whether UUO alters tubular Rho activity. To this end, control and UUO samples were stained 
with an activation-specific antibody that selectively binds to the GTP-bound form of RhoA (Fig. 3a). Active 
RhoA labeling, predominantly in the tubular epithelium, was markedly stronger in 1- and 3-day UUO sections 
Figure 2. RhoA is a central mediator of mechanostress-induced expression of fibrogenic cytokines and nuclear 
translocation of MRTF and TAZ. LLC-PK1 cells, grown to confluence on Flexcell membranes, were pretreated 
with vehicle (DMSO) or the RhoA GTPase inhibitor Rhosin (10 μM) for 30 min and then left unstimulated 
or exposed to cyclic stretch (10% elongation 1 Hz) for 3 h. (a) mRNA levels for the indicated cytokines were 
determined by qPCR as in Fig. 1 (mean ± S.D, n = 3–6). (b). At the end of the experiments, cells on the Flexcell 
membranes were fixed and processed for immunostaining for MRTF and TAZ, as indicated. DAPI was used 
as a nuclear marker. Note that Rhosin prevented the stretch-induced increase in the mRNA level of each of the 
investigated cytokines and inhibited the nuclear translocation of both MRTF and TAZ. Scale bar: 10 μm.
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compared to sham samples. Typically the signal was diffuse at day 1, while at day 3 a more pronounced membrane 
staining was evident in tubular cells. Quantification of full kidney sections revealed significantly elevated levels at 
both times, the earlier response being stronger (Fig. 3b).
Since various fibrogenic stimuli were shown to induce MRTF expression, activation and nuclear translo-
cation in cultured cells32,65–67, we next examined if UUO altered MRTF expression or distribution in kidney 
samples (Fig. 3c). Immunostaining revealed that UUO provoked a rapid and substantial increase in both 
Figure 3. Early UUO provokes RhoA GTPase activation and increases total and nuclear MRTF expression in 
tubular cells. Mice were sham operated or underwent UUO (1 or 3 days as shown), as described in the Methods. 
(a,b) Renal tissue sections were processed for immunohistochemical analysis using a primary antibody specific 
for active RhoA. Nuclei were stained with DAPI. Bar: 50 μm (a). Intensity of the labeling was quantified in >20 
selected areas of 100 μm diameter/animal in 2–3 animals in each group, using the Zen software. The intensities 
were background corrected by subtracting the average labeling obtained in samples exposed to the secondary 
antibody only. (c) Immunohistochemical staining was performed for MRTF-A (upper panels) or MRTF-B 
(lower panels on kidney section obtained after sham (n = 3) 1-day (n = 4) or 3-day (n = 3) UUO surgery. Bar: 
50 µm. (d) Staining intensities were quantified as in (a) using 5–7 randomly selected fields in 3 sham and 4 UUO 
animals in each group. (e) Whole kidney extracts were prepared from sham (n = 3) or UUO-treated mice (3 
days, n = 4) and mRNA levels for MRTF-A (upper panel) and MRTF-B (lower panel) were quantified by qPCR.
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MRTF-A and MRTF-B labeling, predominantly in the tubular epithelium (Fig. 3c, and Supplementary Fig. 2a–e). 
Quantitation showed a several-fold difference compared to the sham levels after both 1- and 3-day UUO (Fig. 3d, 
Supplementary Fig. 2a–d) and this effect persisted even at day 7 (Supplementary Fig. 2f,g). This rise seemed to 
proportionally affect the cytosolic and nuclear compartments. Image analysis showed that the nuclear content of 
MRTF, the driver of MRTF-dependent transcription, was significantly higher in the UUO- treated kidneys than 
in the sham ones (Supplementary Fig. 2c,e). To verify changes in MRTF expression by an independent method, 
we performed qPCR; UUO induced a significant rise in both MRTF-A and B mRNA (Fig. 3e and Supplementary 
Fig. 2h for 7 day UUO).
Having seen that UUO promoted RhoA/MRTF signaling in the epithelium, we set out to determine the poten-
tial role of MRTF in TAZ status and the cytokine responses. To this end, mice were distributed into three treat-
ment groups that underwent sham operation, UUO (3 days) or CCG-1423 treatment plus UUO (3 days). The 
drug was administered intraperitoneally each day, starting at the day of the surgery. Since our recent studies 
showed that MRTF promotes TAZ expression in vitro35,48 and that UUO elevates renal TAZ levels48, we tested if 
CCG-1423 might impact this response. As expected, 3-day UUO significantly increased total renal TAZ mRNA 
and protein expression, as revealed by qPCR, Western blotting and quantified immunohistochemistry (Fig. 4). 
Staining visualized a robust rise in TAZ expression in the epithelium, which was accompanied by enhanced 
nuclear localization (Fig. 4d). Importantly, CCG-1423 treatment strongly mitigated the UUO-associated increase 
in TAZ mRNA and protein expression (Fig. 4a–e) Together these results indicate that TAZ expression increases 
in the injured kidney in an MRTF-dependent manner.
As TGFβ1 is the major driver of fibrogenesis, we investigated its renal expression. Early UUO resulted in 
substantial (5–10-fold) increase in TGFβ mRNA (Fig. 5a) and protein (Fig. 5b,c) expression. Importantly, both 
responses were significantly suppressed by CCG-1423 treatment (Fig. 5a–c). In agreement with previous reports29 
immunohistochemical TGFβ1 staining showed some glomerular labeling with faint and sparse interstitial signal 
under basal conditions. UUO increased tubular/peritubular and interstitial TGFβ labeling (Fig. 5d). We also 
detected stronger glomerular staining. Overall quantitation showed that the number of positive (higher than 
background) pixels doubled. Importantly CCG-1423 abolished this increase (Fig. 5e). Next, we examined the 
expression of fibrogenic cytokines CTGF, PDGF and IHH (Fig. 5f,h). UUO caused significant increases in mRNA 
Figure 4. The MRTF inhibitor CCG-1423 suppresses the UUO-induced rise in renal TAZ mRNA and protein 
expression. (a–c) Whole kidney extracts were prepared from mice 3 days after sham or UUO surgery and 
analyzed for TAZ mRNA by qPCR (a) (mean ± S.D., n = 5/per group), or TAZ protein using Western blotting 
(b,c). Representative blots are shown from 3 animals (b). Protein levels were quantified by densitometry and 
normalized to tubulin (n = 5/per group) (c). (d,e) TAZ was visualized by immunohistochemical staining in 
kidney sections from sham, UUO or CCG-1423-treated UUO mice (d). Images were quantified by determining 
the number of pixels above the threshold under the various conditions, and expressed as fold change compared 
to sham. At least 10 fields were analyzed from 2 randomly selected animals in each group (e) (mean ± .S.E., 
n > 20/group). Bar 200 μm.
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levels of CTGF, PDGF and IHH. CCG-1423 treatment fully abolished the rise in CTGF expression whereas PDGF 
and IHH were not affected. This suggests that while CTGF expression is robustly MRTF-dependent, alternative 
pathways are sufficient to drive expression of PDGF and IHH during UUO.
Inhibition of MRTF suppresses tubular expression of TAZ, TGFβ1 and CTGF. Although sug-
gestive, the above experiments do not directly show that CCG-1423 affected tubular (i.e. epithelial) transcrip-
tional responses for TAZ and cytokines under UUO conditions. To address this crucial point, we collected 
Figure 5. The impact of MRTF inhibition on whole kidney expression of various fibrogenic cytokines during 
UUO. (a–e) Renal TGFβ1 expression. Whole kidney extracts were prepared from sham, 3-day UUO and CCG 
1423-treated UUO mice as in Fig. 4, and TGFβ mRNA (a) and protein (b,c) levels were determined by qPCR 
(mean ± S.D., n = 5/per group) (a) and western blotting (b) followed by densitometry (c), respectively. TGFβ1 
protein expression was normalized to tubulin (Tub) in the same samples. The representative blot shows the 
result from 3 animals from each group. (Quantitation, n = 4–6/group). Note that two bands were visualized, 
likely corresponding to pro- and mature forms of TGFβ; both bands were quantified by densitometry. To 
assess localization, kidney sections were stained for TGFβ (d) and the staining intensities were quantified 
by determining the pixel percentage above background as in Fig. 4. Bar: 200 μm. The mRNA levels for other 
fibrogenic cytokines, namely CTGF (f), PDGF (g) and IHH (h) were determined from the same samples by 
qPCR (mean ± S.D., n = 3–5/per group). Note that UUO caused a significant increase in the expression of all 
investigated cytokines, of which the increases in TGFβ1 and CTGF expression were significantly attenuated by 
MRTF inhibition.
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tubular samples from each animal group using laser capture microdissection (LCM) and analyzed these with 
micro-qPCR. Using a variety of markers, we have verified the purity of the isolated tubular compartment both in 
sham and UUO kidneys in our previous studies58. LCM revealed that TAZ, TGFβ1 and CTGF mRNA significantly 
increased specifically in the tubules of UUO-challenged animals, and each of these responses was significantly 
inhibited (or in case of CTGF fully abolished) by CCG-1423 treatment (Fig. 6a–c). In agreement with the results 
showing a rise in MRTF protein expression by immunohistochemistry, MRTF mRNA was also significantly and 
specifically increased in the tubular compartment (Supplementary Fig. 2i). Moreover, the UUO-induced MRTF 
protein expression per se was suppressed by CCG-1423 (Supplementary Fig. 2b), suggesting that MRTF may 
regulate its own expression via a positive feedback loop.
Figure 6. MRTF mediates tubular expression of TAZ, TGFβ1 and CTGF during UUO. Kidney sections from 
sham, UUO and CCG-1423-treated UUO mice were mounted on membrane slides and rapidly stained with 
H&E staining. The tubular epithelium was then isolated using laser capture microdissection. Approximately 200 
tubular excisions were collected from each animal, and the obtained material was processed for qPCR to detect 
tubular TAZ (a), TGFβ1 (b), CTGF (c) mRNA levels. Note that mRNA levels of each of these genes increased 
significantly in the tubular epithelium during UUO, and this effect was significantly suppressed by MRTF 
inhibition (mean ± S.D. n = 5/per group).
Figure 7. CCG-1423 treatment reduces early fibrogenesis during UUO. To assess early fibrogenesis, kidney 
sections were stained for fibrillary collagen using picrosirius red (PSR), and for Collagen IV and α-smooth 
muscle actin (α-SMA) using the respective antibodies. Quantitative immunohistochemistry revealed a 
significant increase in the levels of all of these fibrosis markers, an effect that was abolished or mitigated 
by CCG-1423 treatment; 3–5 randomly chosen fields/animal were quantified in 2 animals in each group 
(mean ± S.E., n = 6–10/per group). Similar results were obtained by whole-specimen scanning using a Huron 
Technologies TissueScope scanner and the TissueStudio analysis software (not show).
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In contrast, we could not detect a rise in IHH in the tubules whereas PDGF remained below the level of detect-
ability in both control and UUO conditions (data not shown). Taken together, UUO increases renal tubular TAZ, 
TGFβ1 and CTGF expression in an MRTF-dependent manner.
CCG-1423 inhibits fibrogenesis in the early phase of UUO. Finally, we assessed if CCG-1423 could 
exert overall antifibrotic effects in UUO. We therefore stained kidney samples for classical markers of ECM pro-
duction (PSR or fibrillar collagens, and Collagen IV) and myofibroblast transition (α-SMA) (Fig. 7). Quantitative 
image analysis revealed that each marker increased in the interstitial compartment upon 3-day UUO, and that 
each was significantly suppressed by CCG-1423 treatment. Thus, inhibition of MRTF effectively mitigated 
obstructive nephropathy-induced fibrosis.
Discussion
The central conceptual novelty of this work is the demonstration that MRTF and TAZ are key contributors 
to the development of the profibrotic epithelial phenotype, as these factors act as indispensable mediators of 
injury-induced epithelial production of fibrogenic cytokines. Furthermore, to our best knowledge our study is the 
first to show in situ activation of RhoA and increased expression/activation of MRTF in the tubular epithelium 
in a relevant animal model of fibrosis. While MRTF-A knockout mice have been found to be partially protected 
against diabetic nephropathy50 and genetic or pharmacological interference with MRTF mitigated fibrosis in 
various other organs (e.g. heart, liver, lung, and skin/systemic49,68–71), these effects were attributed to a direct 
role of MRTF in fibroblast activation (e.g. collagen and fibronectin production) and injury- or TGFβ-induced 
fibroblast-myofibroblast transition. Our own studies have shown a key role for MRTF in full-blown EMyT and 
α-SMA expression31,32. While these effects undoubtedly contribute to the fibrogenic activity of MRTF, our current 
studies suggest that MRTF also plays a central role in the initial, epithelial phase of fibrogenesis by mediating the 
synthesis of fibrogenic cytokines. Inhibition of MRTF by CCG-142360,72 or its recently developed derivatives (e.g. 
CCG-203971), which have better bioavailability and efficacy73 represents a promising antifibrotic intervention 
for several reasons. First, due to the dual role of MRTF, they target both the epithelial and the mesenchymal 
compartments of fibrogenesis. Second, they act directly on MRTF (masking its nuclear localization signal59) i.e. 
downstream of RhoA without interfering with the non-transcriptional, widespread effects of this GTPase. Third, 
MRTF emerges as a master regulator of fibrogenic (partial or complete) phenotypic transitions. This conclusion is 
supported by our previous and current findings that (1) MRTF is a transcriptional driver of TAZ expression35,48; 
(2) TAZ levels increase during fibrogenesis in the whole kidney48 and, as our LCM results now show, specifically 
and predominantly in the tubular epithelium; and (3) increased renal/tubular TAZ expression is inhibited by 
CCG-1423. Moreover, elegant studies by Grande at al.24 have revealed that epithelial expression of Snail, another 
major EMT-inducing transcription factor is both necessary and sufficient to induce partial EMT accompanied 
by an increase in renal TGFβ1 levels and fibrosis. Interestingly MRTF was shown to drive Snail/Slug expression46, 
thus it is conceivable that MRTF is one of the key transcription factors responsible for the rise in epithelial Snail 
as well. In any case, the fact that three EMT-inducing transcription factors, MRTF, TAZ and Snail, are activated or 
overexpressed in the tubular epithelium during fibrosis gives strong credence to the notion that EMT, at least in 
its partial form (PEP), does occur during, and significantly contributes to the ensuing pathology.
We found that during UUO MRTF protein levels increased in the tubular epithelium and this effect, at least 
in part may underlie augmented MRTF activity. While the mechanisms regulating MRTF expression have not 
been extensively characterized, actin remodeling and TGFβ were reported to increase MRTF mRNA in an 
SRF-dependent manner65,66. Our data showing that MRTF expression per se was mitigated by CCG-1423 during 
UUO are consistent with an MRTF/SRF-dependent positive feedback loop for the expression of both proteins, 
a possibility that warrants further studies. In addition, increased RhoA signaling was also proposed to stabilize 
MRTF protein67. Taken together an initial activation of the RhoA/MRTF pathway may lead to increased MRTF 
expression. This, along with the consequent TAZ expression will lead to enhanced cytokine production, thereby 
generating a fibrogenic positive feedback loop.
Of the two main Rho-sensitive Hippo pathway effectors, in this study we have concentrated on TAZ, as UUO 
had a much stronger effect on this protein than YAP48, and TAZ but not YAP is driven by MRTF35,48. However, 
YAP is also emerging as a fibrogenic mediator74–76. Arguably, the relative contribution of TAZ vs. YAP might 
depend on the type of the fibrosis-initiating injury.
Our studies show that MRTF and TAZ are activated in mechanically challenged renal tubular cells, and both 
are critical for production of the most important fibrogenic cytokines. The underlying mechanisms can be both 
direct and indirect. Consistent with the first possibility, the CTGF promoter is known to be regulated via MRTF/
SRF-driven CArG boxes, and TAZ/YAP/TEAD-driven cis-elements. Further, large-scale (ChIP-seq, microarrays) 
analyses have predicted SRF/MRTF-responsive CArG boxes in the promoters of TGFβ1 and PDGF-A77, and 
TAZ/YAP responsiveness for TGFβ278. Nonetheless the importance of these elements under pathophysiological 
conditions was not assessed. Indirect mechanisms may include regulation of upstream elements of the mech-
anotransduction pathways. For example, MRTF is known to affect β1-integrin expression, and mechanical induc-
tion of TGFβ1 production was recently shown to be mediated by the β1 integrin/Src/Stat3 pathway79. It remains to 
be tested if MRTF and/or TAZ/YAP inhibition exert their effects partially via interfering with upstream elements 
of mechanosensitive routes. The MRTF-dependence of TAZ expression is one but likely not the only mechanism 
whereby MRTF inhibition acts, as judged by the presence of CArG boxes in the target genes and the fact that 
TAZ translocation is not affected by MRTF inhibition35. In agreement with our data, a recent study reported 
that deletion of the Hippo pathway adaptor Salvador1, which results in increased TAZ expression, enhanced 
UUO-induced fibrosis and the expression of TGFβ2 and the TGFβ II receptors in vitro80.
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Little is known about the mechanoregulation of IHH. One study indicated that stretch induces IHH pro-
duction in chondrocytes81, and a recent paper proposed that TAZ can activate IHH expression in non-alcoholic 
steatohepatitis82. Further work should clarify direct and/or indirect regulation.
It is noteworthy that the MRTF/TAZ-dependent cytokine production demonstrated herein represents a 
vicious circle: MRTF and TAZ activate TGFβ1 production and ECM deposition (stiffness) and both of these 
factors are known to activate MRTF and TAZ/YAP. Further, we have shown that the TGFβ-provoked TAZ expres-
sion is MRTF-dependent in vitro48, and a recent study published during the completion of this report reveals 
that epithelial overexpression of TGFβ can induce epithelial TAZ expression83. Such positive feedback loops are 
characteristic of rapid fibrogenesis, and breaking them may signify an efficient therapeutic approach. Of note, the 
in vitro and in vivo results overlap but are not identical; while CCG-1423 potently inhibited all of the 
stretch-induced cytokine responses in LLC-PK1 cells (proof of principle), CCG-1423 treatment reduced TAZ, 
TGFβ1 and CTGF but not PDGF or IHH in the injured kidney. In the tubular epithelium CCG-1423 suppressed 
the rise in tubular TAZ, TGFβ1 and CTGF, whereas at this early time point we did not see a rise in tubular IHH, 
and could not detect PDGF mRNA. The likely explanation is that these cytokines are driven by alternative mech-
anisms in vivo and/or that non-epithelial cells may be their major sources. The emerging picture is that activation 
of fibrogenic pathways both in the epithelium and in the mesenchyme contribute to fibrosis. In accordance with 
this notion, a recent study shows that fibroblast-specific deletion of YAP and TAZ mitigates but does not prevent 
fibrosis84.
The roles of MRTF and TAZ/YAP are by no means restricted to mechanically induced/promoted fibrosis. 
For example, MRTF can be activated by TGFβ1 and oxidative stress48,85, while the prime regulator of TAZ/YAP 
signaling is the Hippo pathway, which integrates humoral, metabolic, and polarity-associated inputs37,44. Indeed, 
evidence is accumulating that MRTF and TAZ/YAP play a significant role in a variety of experimentally induced 
fibrosis models (e.g.48–50,53,72,80,86) forecasting a central role for these factors in clinical disease as well.
Beside cytokine production, PEP is also associated with oxidative changes (e.g. Nox4 expression), cellular senes-
cence and alteration in the cell cycle (G2/M block)87. We have shown that both MRTF and TAZ contribute to Nox4 
expression58, and a recent study reported that MRTF upregulates Nox1 and 4 in macrophages in the context of acute 
kidney injury88. Nonetheless, it remains to be tested if MRTF and TAZ/YAP participate in the other key features of PEP.
In summary, our study reveals that MRTF and TAZ play central roles in the development of PEP, a process 
hallmarked by epithelial cytokine production, which in turn may play a key role in the early, triggering phase of 
fibrogenesis via epithelial-mesenchymal interactions.
Materials and Methods
Cells and reagents. LLC-PK1 (Cl 4) cells (porcine kidney tubular epithelial cells, a gift from R. C. Harris, 
Vanderbilt University School of Medicine, Nashville, TN), were maintained in DMEM containing 1 g/L glucose and 
sodium pyruvate and supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen).
Reagents: TGFβ1 and Rhosin hydrochloride were from R&D Systems (Minneapolis, MN), CCG-1423, 
verteporfin, 3,3′-Diaminobenzidine (DAB) and picrosirius red (PSR) from Sigma Aldrich (St. Louis, MI). 
Antibodies were from the following sources: TAZ and TGFβ: Abcam (Cambridge, UK); MRTF-A: Cell Signaling 
Technologies (Danvers, MA); MRTF-B: Santa Cruz Biotech (Dallas, TX), tubulin: Sigma Aldrich (St. Louis, MI); 
active RhoA: New East Biosciences (King of Prussia, PA); Collagen IV: Southern Biotech (Birmingham, AL); 
horseradish peroxidase-coupled antibodies: Jackson ImmunoResearch Laboratories; Alexa 488 or 555-coupled 
antibodies: Invitrogen. 4,6-Diamidino-2-phenylindole, dihydrochloride (DAPI) was from Lonza.
All methods applied in this study were performed in accordance with the relevant guidelines and regulations 
of Scientific Reports and the Keenan Research Centre/St. Michael’s Hospital.
siRNA-mediated silencing. Transfection with siRNA was performed using Lipofectamine RNAiMAX 
(Invitrogen). Forty-eight h post transfection cells were serum depleted for 3 h and subjected to cyclic stretch 
as described below. Porcine-specific siRNAs (Thermo-Fisher or Sigma-Aldrich) were against the following 
sequences: TAZ 5′-GGAAGAAGATCCTGCCTGA-3′; MRTF-A 5′-AACCAAGGAGCUGAAGCCAAA-3′; and 
MRTF-B 5′-AACGACAAACACCGTAGCAAA-3′35. siRNAs for MRTF-A and MRTF-B were used simultane-
ously at 50 nM each, and for TAZ at 50 nM. Non-related (NR) control siRNA (Applied Biosystems) was used 
under the same experimental conditions.
Mechanical cell stretch. Cells were grown on six-well plates with untreated flexible bottoms (BioFlex cul-
ture plates), and serum-depleted overnight. Where indicated, 5 μM CCG-1423 or 1 μM verteporfin were added 
for 30 min prior to stretching. Similar drug doses were shown to be effective and non-toxic in previous in vitro 
studies by us and others53,58,89,90. Cells were subjected to 60 cycles/min stretch (0.5 s of stretch (10%) and 0.5 s of 
relaxation) for 3 h in a humidified 5% CO2 incubator at 37 °C using Flexcell 5000. Control cells were grown on the 
same flexible surface but not subjected to mechanical stretch.
Unilateral Ureteral Obstruction (UUO). The UUO procedure was described in53,58. Briefly, 6–8 weeks old 
male C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) were randomized to receive an intraperitoneal injection 
of 1.5 mg/kg CCG-1423 or saline prior to surgery, and daily post-surgery. This dose was chosen according to pre-
vious studies showing CCG-1423 efficacy without toxicity72. During surgery the left ureter was tied (UUO) or left 
undisturbed (sham). At 3 days post-surgery the mice were sacrificed, the left kidneys were harvested, and the tissue 
was either snap-frozen in liquid nitrogen (for RNA and protein), or embedded in Optimum Cutting Temperature 
(OCT) medium and snap-frozen (for LCM), or fixed and embedded in paraffin (for IHC). Samples were stored at 
−80 °C until processed. The animal care committee of the St. Michael’s Hospital approved this study.
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Real Time Quantitative PCR. Total RNA from whole kidneys or LLC-PK1 cells was purified using Total 
RNA Mini Kit (Geneaid, New Taipei City, Taiwan), or the RNeasy mini kit (Qiagen, Venlo, Netherlands), respec-
tively. RNA was reverse-transcribed using iScriptTM kit (Bio-Rad), and SYBR-green-based PCR was performed 
and analyzed as described in48. Primers are listed in Table 1. Data were analyzed using iQ5 software. Melt curves 
confirmed the presence of one amplicon. Quantification of mRNA was done using the Livak Method.
Laser Capture Microdissection. LCM was described in58. Briefly, OCT embedded mouse kidney sections 
were stained using Mayer’s hematoxylin and eosin Y solution (Sigma). LCM was performed using the Leica 
LMD laser capture microdissection system (Leica Microsystems GmbH, Wetzlar, Germany). A total of ≈200 
tubular cuts were captured for each sample. Total RNA was isolated using the RNeasy micro RNA isolation kit 
(Qiagen) and reverse-transcribed using iScriptTM reverse transcription (Bio-Rad) and qPCR was performed 
using QuantiFast SYBR Green (Qiagen) with the primers listed in Table 1.
Preparation of whole kidney lysates. Kidney samples were processed as described in58. Briefly, kidney 
samples were lysed using ice-cold RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS, and 1 mM EDTA) supplemented with 1 mM Na3VO4, 1 mM phenylmethylsul-
fonyl fluoride, and Complete Mini Protease Inhibitor (Roche Applied Science, Mississauga, Ontario, Canada), 
homogenized and centrifuged. Supernatants were used for Western blotting.
Western Blotting. SDS-PAGE and Western blotting were performed as in48. The blots were developed using 
enhanced chemiluminescence (GE Healthcare, Mississauga, Ontario, Canada), and the signal was captured with 
a ChemiDoc system (Bio-Rad). Where indicated, blots were stripped and reprobed to demonstrate equal load-
ing or to detect levels of down-regulated proteins. Quantification was performed using the ImageLab software 
(Bio-Rad). Extended blots are shown in Supplementary Fig. 1.
Immunofluorescence microscopy. Cells grown on glass coverslips or BioFlex membranes were transfected 
and/or treated as indicated. The staining was performed as in35. Images were captured using an Olympus IX81 
microscope coupled to an Evolution QEi Monochrome camera using MetaMorph software or a Zeiss AxioObserver 
microscope, and analyzed by the Zen Blue software. Background staining was determined and subtracted using par-
allel staining with secondary antibody only. Representative images are shown from each condition in a minimum of 
three independent experiments. All image processing was done according to the Journal’s guidelines.
Immunohistochemistry and quantification. Staining of paraffin embedded kidney sections was per-
formed as in53. Histological slides were viewed by an Olympus BX50 microscope driven by the Cellsense soft-
ware, and analyzed using Fiji software91. To quantify the amount of DAB or PSR-positive pixels in each image, 
color deconvolution was applied, followed by thresholding. The number of positive pixels was then expressed 
as fold change compared to sham condition. Additional image analysis was also performed using the Axio Scan 
Z1 slide scanner driven by the Zen software and the Halo V2.3 program, as described in detail in the legend to 
Supplementary Figure 2.
Statistical Analysis. Data are presented as representative blots or images from at least three similar experi-
ments or as means for the number of experiments indicated ± standard deviation (S.D.) or standard error (S.E.), 
as indicated. Statistical significance was determined by one-way analysis of variance (Tukey post hoc testing for 
parametric analysis of variance), using Prism software. p < 0.05 was accepted as significant. p < 0.05; **p < 0.01; 
***p < 0.001 and ****p < 0.0001.
ID Sense Antisense
Murine MRTF-A 5′-TTG TCC CAG CCT GGT TCT CCA-3′ 5′-ATC TGC TGA AAT CTC TCC ACT CTG-3′
Murine MRTF-B 5′CCC CAG CAG TTT GTT GTT CAG CACT CTT-3′ 5′- GAT GCT GGC TGT CAC TGG TTT CAT CTT G-3′
Murine TAZ 5′-GAC GAG ATG GAT ACA CCT GAA-3′ 5′-GAA GGC AGT CCA GGA AAT CA-3′
Murine TGFβ1 5′-GAA GGG CCG GTT CAT GTC ATG-3′ 5′-TGT GAC AGC AAA GAT AAC AAA CTC CAC-3′
Murine PDGF-B 5′-CCC ACA GTG GCT TTT CAT TT-3′ 5′-GTG AAC GTA GGG GAA GTG GA-3′
Murine CTGF 5′- TTG TAA TGG CAG GCA CAG GTC -3′ 5′- CGC ACA AGA ACC ACC ACT CTG -3′
Murine IHH 5′-GCT CAC CCC CAA CTA CAA TC-3′ 5′-GCG GCC CTC ATA GTG TAA AG-3′
Murine GAPDH 
(reference gene) 5′- TGC AGT GGC AAA GTG GAG ATT-3′ 5′-TTG AAT TTG CCG TGA GTG GA-3′
porcine TGFβ1 5′-CTG TGT CTG TCC ACC ATT CA-3′ 5′- GGT CCA AGA TGC TCA GTA AGT-3′
porcine TGFβ2 5′-TTG ATG GCA CCT CCA CAT ATA C-3′ 5′-TGT AGG AGG GCA ACA ACA TTA G-3′
Porcine CTGF 5′-GTG AAG ACA TAC CGG GCT AAG-3′, 5′-GAC ACT TGA ACT CCA CAG GAA-3′
Porcine PDGF-B 5′-CAA GTG TGA GAC GGT GGT GG-3′ 5′-GCG GGG CTG AAC AAT TAG AG-3′
Porcine IHH 5′-CTT GCA GCG CTG GGT CAT-3′ 5′-CGC TAT GAA GGC AAG ATC GC-3′
Porcine GAPDH 
(reference gene) 5′-GCA AAG TGG ACA TGG TCG CCA TCA-3′, 5′-AGC TTC CCA TTC TCA GCC TTG ACT-3′
Table 1. Primers used in the study.
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Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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